ADVERTISEMENT
ACC.24: DanGer Shock Randomized Controlled Trial Confirms Impella CP Improves Survival in Heart Attack with Cardiogenic Shock
DANVERS, Mass. – A late-breaking clinical trial, presented at the American College of Cardiology conference and simultaneously published in the New England Journal of Medicine, confirms routine use of Impella CP in patients who have had a heart attack with STEMI cardiogenic shock reduces 180-day mortality by 12.7%, compared to the control arm (45.8% vs. 58.5%, p=0.04).
The Danish German Cardiogenic Shock Trial (DanGer Shock) randomized controlled trial (RCT) is the first mechanical circulatory support device RCT to demonstrate a survival benefit in AMI cardiogenic shock patients. The trial enrolled 360 participants at 14 sites in Denmark, Germany and the United Kingdom between 2013-2023[1].
“We congratulate Dr. Møller and the independent group of investigators who initiated and completed this landmark trial,” said Chuck Simonton, MD, EVP and chief medical officer, Abiomed. “What impresses me most is that the significant survival benefit with Impella, compared to the control arm, improves over time.”
Approximately 750,000 people in the United States experience a ST-elevation myocardial infarction (STEMI), an acute heart attack, each year2 and the overall incidence rate of cardiogenic shock in patients with STEMI is up to 10%3. Cardiogenic shock (CS) is the leading cause of in-hospital mortality in patients with ST-segment elevation myocardial infarction (STEMI) 4.
The authors state that the increased risk of adverse events does not overshadow the benefit of treatment with Impella CP, a microaxial flow pump.
______________________________
1 Moller, et al., New England Journal of Medicine, 7 Apr 2024
2 Abe, et al., Journal of the American Heart Association, 27 Feb 2023.
3 Kolte, et al., Journal of the American Heart Association, 13 Jan 2014
4 Cosentino, et al., Journal of Clinical Medicine, 21, May, 2021
Find More:
The Latest Clinical & Industry News
Grand Rounds With Morton Kern, MD
